A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective is to determine the rates & routes of excretion of 14C radiolabelled AZD2171 in patients by assessment of concentrations of total 14C radioactivity and AZD2171 in plasma & concentrations of total radioactivity in urine&faeces
assessed at time intervals post dose
No
Nick Botwood, BSc, MBBS, MRCP, MFPM
Study Director
AstraZeneca
United Kingdom: Medicines and Healthcare Products Regulatory Agency
D8480C00019
NCT00503412
November 2005
May 2006
Name | Location |
---|